Skip to content

Study · Randomized controlled trial · n = 8 · 2003

3 results

The effect of glucagon-induced gastric relaxation on TLOSR frequency.

Chang HY, Pandolfino JE, Shi G, Boeckxstaens GE, Joehl RJ, Kahrilas PJ

Neurogastroenterology and motility1 Feb 2003Cited by 5 (Europe PMC)

PMID12588463 (opens in a new tab)DOI10.1046/j.1365-2982.2003.00386.x (opens in a new tab)PepBankPUB-12588463
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In normal subjects, glucagon increased fundal relaxation versus placebo (P < 0.05).

    In plain wordsIn healthy participants, glucagon relaxed the upper stomach more than placebo.

    Peptide
    Glucagon
    Outcome
    IncreaseFundal relaxation
    Study

    n = 8

    Comparator
    placebo (saline)
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    4.8 microg kg(-1) bolus followed by 9.6 microg kg(-1) h(-1) infusion · 1 hourAs given in this study (human).

    Source sentences

    Summary
    Glucagon induced significant fundal relaxation compared with placebo (P < 0.05) and significantly decreased baseline LEOS pressure (P < 0.05).
    2 context sentences
    Summary · context
    Eight normal subjects (four male, age 18-52 y) were studied after a 6-h fast using a combined manometric barostat assembly.
    Summary · context
    Patients were studied on two different days and randomly received glucagon (4.8 microg kg(-1) bolus followed by 9.6 microg kg(-1) h(-1) infusion) on 1 day and placebo (saline) on another.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In normal subjects, glucagon did not alter transient lower esophageal sphincter relaxation frequency compared with placebo.

    In plain wordsIn healthy participants, glucagon did not change transient lower esophageal sphincter relaxation frequency compared with placebo.

    Peptide
    Glucagon
    Outcome
    No significant changeTransient lower esophageal sphincter relaxation frequency
    Study

    n = 8

    Comparator
    placebo (saline)
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    4.8 microg kg(-1) bolus followed by 9.6 microg kg(-1) h(-1) infusion · 1 hourAs given in this study (human).

    Source sentences

    Summary
    The frequency of TLOSRs was not altered by glucagon infusion compared with placebo.
    2 context sentences
    Summary · context
    Eight normal subjects (four male, age 18-52 y) were studied after a 6-h fast using a combined manometric barostat assembly.
    Summary · context
    Patients were studied on two different days and randomly received glucagon (4.8 microg kg(-1) bolus followed by 9.6 microg kg(-1) h(-1) infusion) on 1 day and placebo (saline) on another.
  3. 03HumanNon-randomized trialEfficacy outcome

    In normal subjects, glucagon decreased baseline lower esophageal sphincter pressure (P < 0.05).

    In plain wordsIn healthy participants, glucagon reduced lower esophageal sphincter pressure from baseline.

    Peptide
    Glucagon
    Outcome
    DecreaseBaseline lower esophageal sphincter pressure
    Study

    n = 8

    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    4.8 microg kg(-1) bolus followed by 9.6 microg kg(-1) h(-1) infusion · 1 hourAs given in this study (human).

    Source sentences

    Summary
    Glucagon induced significant fundal relaxation compared with placebo (P < 0.05) and significantly decreased baseline LEOS pressure (P < 0.05).
    2 context sentences
    Summary · context
    Eight normal subjects (four male, age 18-52 y) were studied after a 6-h fast using a combined manometric barostat assembly.
    Summary · context
    Patients were studied on two different days and randomly received glucagon (4.8 microg kg(-1) bolus followed by 9.6 microg kg(-1) h(-1) infusion) on 1 day and placebo (saline) on another.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.